Eylea HD 8 MG/0.07 ML vial 0.07ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQQE3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $58,526
Award facts
- Contract value 100% obligated
- $58,526.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $58,526.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA HD 8 mg/0.07 ml vials. The award, issued on February 4, 2026, with an ultimate completion date of February 26, 2026, carries no set-aside designation, indicating the company competed on an unrestricted basis. DMS Pharmaceutical Group was selected as the awardee under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply the Department of Defense's pharmaceutical and medical consumable requirements globally.
This delivery order represents a routine pharmaceutical procurement supporting DOD military healthcare operations. DMS Pharmaceutical Group's established performance across numerous delivery orders and its single-award Indefinite Delivery Contract under PPV-G GEN V—valued at $499,999,999 through December 31, 2036—demonstrate the company's capability to serve as a critical pharmaceutical supplier for the federal military medical system. The company's comprehensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, positioning it to fulfill the diverse medical supply needs of DOD healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FQQE3?
SPE2DR26FQQE3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FQQE3 worth?
The government has obligated $58,526 on SPE2DR26FQQE3.
Is contract SPE2DR26FQQE3 an order under another contract?
Yes. SPE2DR26FQQE3 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQE3 competed?
The extent of competition for SPE2DR26FQQE3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award